Adam Boxer, MD
Neurology · San Francisco, CANPI 1841231800
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by H. Lundbeck A S at 28.2% of the total. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $1083.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- H. Lundbeck A S$37K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$28K
- Merck$14K
- Janssen Global Services, LLC$10K
- Eisai Inc.$7K
- Eli Lilly$7K
- plus $28K from 18 others
Across 113 payments — averaging $47,297 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$2.6M
- Regeneron$1.5M
- Eisai Inc.$932K
- F. Hoffmann-la Roche AG$176K
- Genentech, Inc.$166K
- Janssen Research & Development, LLC$4K
- plus $3K from 2 others
What the payments were for
- Consulting fees$74,54657%
- Speaking & faculty fees$24,29019%
- Travel & lodging$27,81421%
- Food & beverage$3,3453%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| H. Lundbeck A S | 11 | $36,675 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $27,718 |
| Merck | 16 | $13,558 |
| Janssen Global Services, LLC | 11 | $9,971 |
| Eisai Inc. | 11 | $7,345 |
| Eli Lilly | 18 | $7,104 |
| F. Hoffmann-la Roche AG | 2 | $4,440 |
| E.r. Squibb & Sons, L.L.C. | 3 | $3,152 |
| Genentech, Inc. | 2 | $2,921 |
| Pfizer | 1 | $2,450 |
| Roche Products Limited | 2 | $2,400 |
| Janssen Research & Development, LLC | 1 | $2,115 |
| Genentech USA, Inc. | 1 | $2,070 |
| Boehringer Ingelheim International GmbH | 1 | $2,000 |
| AstraZeneca | 1 | $1,500 |
| GSK | 2 | $1,380 |
| Biogen | 6 | $905 |
| Regeneron | 1 | $790 |
| UCB Biosciences Inc. | 1 | $500 |
| Neurocrine Biosciences, Inc. | 8 | $423 |
| Boston Scientific | 5 | $239 |
| Otsuka Pharmaceutical Co., Ltd. | 8 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $105 |
| UCB SA | 1 | $38 |
How this compares
$129,995 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 16 | $115 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Francisco
- S Claiborne JohnstonSan Francisco$576K
- Armen MoughamianSan Francisco$554K
- Scott ZamvilSan Francisco$447K
- Bruce CreeSan Francisco$412K
- Kenneth LaxerSan Francisco$379K
- Jonathan KatzSan Francisco$294K
- Nada HindiyehSan Francisco$268K
- Douglas GoodinSan Francisco$227K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.